Floatz logo

Anti-IL13Ralpha2 CAR T-cells

Recurrent Glioblastoma, IDH-Wildtype

City of Hope Medical CenterPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

39 Active assets in the Recurrent Glioblastoma, IDH-Wildtype cohort.

Asset / SponsorPhaseRating
Ipilimumab
Neonc Technologies, Inc.
Phase 2B
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
National Cancer Institute (NCI)
Phase 2B
Pembrolizumab
Mayo Clinic
Phase 2B
Nivolumab
Neonc Technologies, Inc.
Phase 2B
Cerebraca Wafer
Everfront Biotech Co., Ltd.
Phase 2/3B

View all 44 →

Same molecule, other indications

Anti-IL13Ralpha2 CAR T-cells is also rated in:

astrocytoma, IDH-mutant, grade 4Dormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →